Evidence map›Paper›PMID 36140429›Full record

ArticleBiomedicines2022

Clinical Performance of Self-Collected Nasal Swabs and Antigen Rapid Tests for SARS-CoV-2 Detection in Resource-Poor Settings.

Nádia Sitoe, Júlia Sambo, Nédio Mabunda, Neuza Nguenha, Jorfélia Chilaúle, Júlio Rafael, Anésio Macicame, Imelda Chelene, Chishamiso Mudenyanga, Jillian Sacks and 3 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Nádia SitoeInstituto Nacional de Saúde, Marracuene 3943, Mozambique.ORCID 0000-0001-7310-8221
Júlia SamboInstituto Nacional de Saúde, Marracuene 3943, Mozambique.ORCID 0000-0002-4246-7085
Nédio MabundaInstituto Nacional de Saúde, Marracuene 3943, Mozambique.
Neuza NguenhaInstituto Nacional de Saúde, Marracuene 3943, Mozambique.
Jorfélia ChilaúleInstituto Nacional de Saúde, Marracuene 3943, Mozambique.
Júlio RafaelInstituto Nacional de Saúde, Marracuene 3943, Mozambique.
Anésio MacicameInstituto Nacional de Saúde, Marracuene 3943, Mozambique.
Imelda CheleneInstituto Nacional de Saúde, Marracuene 3943, Mozambique.
Chishamiso MudenyangaClinton Health Access Initiative, Maputo City 592, Mozambique.ORCID 0000-0002-6945-6693
Jillian SacksWorld Health Organization, 1211 Geneva, Switzerland.
Sofia ViegasInstituto Nacional de Saúde, Marracuene 3943, Mozambique.ORCID 0000-0002-8575-0657
Osvaldo LoquihaClinton Health Access Initiative, Maputo City 592, Mozambique.
Ilesh JaniInstituto Nacional de Saúde, Marracuene 3943, Mozambique.ORCID 0000-0002-6880-6655
Instituto Nacional de Saúde · MZClinton Health Access Initiative · USWorld Health Organization · CH

Funding

Bill & Melinda Gates Foundation #OPP1214435Global Affairs Canada SARS-CoV-2 responseWorld Health Organization 001World Health Organization the SARS-CoV-2 Antigen detecting rapid diagnostic test implementation projects
6 · The paper itself

Abstract

Background: In resource-poor countries, antigen-based rapid tests (Ag-RDTs) performed at primary healthcare and community settings improved access to SARS-CoV-2 diagnostics. However, the technical skills and biosafety requirements inherent to nasopharyngeal and oropharyngeal (OP) specimens limit the scale-up of SARS-CoV-2 testing. The collection of nasal-swabs is programmatically viable, but its performance has not been evaluated in resource-poor settings. Methods: We first evaluated the performance of SteriPack self-collected nasal swabs for the detection of SARS-CoV-2 by real-time PCR in 1498 consecutively enrolled patients with suspected infection. Next, we evaluated the clinical performance of three nasal swab-based Ag-RDTs against real-time PCR on OP specimens. Results: The sensitivity of nasal swabs was 80.6% [95% CI: 75.3−85.2%] compared to OP specimens. There was a good correlation (r = 0.58; p < 0.0001) between Ct values of 213 positive cases obtained using nasal and OP swabs. Our findings show sensitivities of 79.7% [95% CI: 73.3−85.1%] for Panbio COVID-19 Ag-RDT, 59.6% [95% CI: 55.2−63.8%] for COVIOS Ag-RDT, and 78.0% [95% CI: 73.5−82.0%] for the LumiraDx SARS-CoV-2 Ag-RDT. Conclusions: In our setting, the COVIOS Ag-RDT did not meet WHO requirements. Nasal swab-based Ag-RDTs for SARS-CoV-2 detection constitute a viable and accurate diagnostic option in resource-poor settings.

Indexed as

antigen rapid testsclinical evaluationnasal swabsresource-poor settingsself-collection

Identifiers

PMID36140429
PMCPMC9496276
OpenAlexW4296526816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.